Browse All

Current Filters

CLEAR FILTER x

TITLE

Effect of Longer-term Ofatumumab Treatment on Disability Progression and Brain Volume Change

Author:Cohen, Jeffrey   Hauser, Stephen   Zielman, Ronald   Das Gupta, Ayan   Azmon, Amin   Xi, Jing   Mavrikis Cox, Gina   Robertson, Derrick   Wiendl, Heinz   Kappos, Ludwig   

Session Name:S16: MS Clinical Trials and Therapeutics  

Topic:MS and Inflammatory Disease  

Program Number:S16.009  

Author Institution:Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  UCSF Weill Institute for Neurosciences, Department of Neurology, University of California - San Francisco, San Francisco, CA, USA, San Francisco, CA  Central Texas Neurology Consultants, Round Rock, TX, USA, Round Rock, TX  Novartis Pharma B.V., Amsterdam, The Netherlands, Haaksbergweg, Netherlands  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharma A.G., Basel, Switzerland, Basel, Switzerland  China Novartis Institutes for BioMedical Research Co., Ltd, Shanghai, China, Shanghai, China, People's Republic of  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL, USA, Tampa, FL  University of Muenster, Muenster, Germany, Muenster, Germany  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  

Long-term Effect of Ofatumumab Treatment on Serum Neurofilament Light Chain Levels and NEDA-3 Status in Patients With RMS: Results From ASCLEPIOS I/II and ALITHIOS

Author:Alvarez, Enrique   Kuhle, Jens   Kappos, Ludwig   Ziemssen, Tjalf   Arnold, Douglas   Cross, Anne   Boer, Ibolya   Das Gupta, Ayan   Hu, Xixi   Kukkaro, Petra   Kieseier, Bernd   Zielman, Ronald   Hauser, Stephen   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.013  

Author Institution:Department of Neurology, Rocky Mountain MS Center at the University of Colorado, Aurora, CO  Neurology, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland  Center of Clinical Neuroscience, Department of Neurology, University Clinic Carl Gustav Carus, Dresden, Germany  McConnell Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University and NeuroRx Research, Montreal, QC, Canada  Washington University School of Medicine, Saint Louis, MO  Novartis Pharma AG, Basel, Switzerland  Novartis Healthcare, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Novartis Pharma B.V., Amsterdam, Netherlands  UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA